American Society of Clinical Oncology 47th Annual ... - ABCSG

Friday, June 3, 2011FRIDAY2:00 PM - 6:00 PMPOSTER DISCUSSION SESSIONLeukemia, Myelodysplasia, and TransplantationDisplay Time: 2:00 PM - 6:00 PMDisplay Location: E450bDiscussion Time: 5:00 PM - 6:00 PMDiscussion Location: Arie Crown TheaterCME credit: 1Track(s): Leukemia, Myelodysplasia, and TransplantationJane Liesveld, MD—Co-ChairUniversity of Rochester Medical CenterHarry Paul Erba, MD, PhD—Co-ChairUniversity of Michigan Medical CenterDiscussion5:00 PM Olatoyosi Odenike, MD (Abstracts #6509–6515)The University of ChicagoDiscussion5:15 PM Farhad Ravandi, MD (Abstracts #6516–6522)University of Texas M. D. Anderson Cancer CenterDiscussion5:30 PM Joseph P. Uberti, MD (Abstracts #6523–6528)Karmanos Cancer Institute, Wayne State UniversityDiscussion5:45 PM Guido Marcucci, MD (Abstracts #6529–6533)The Ohio State University Comprehensive Cancer CenterBrd. 1 Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phasechronic myeloid leukemia (CP CML) in the BELA trial: Eighteen-monthfollow-up. (Abstract #6509)C. Gambacorti-Passerini, J. E. Cortes, D. Kim, H. Kantarjian, N. Khattry,J. H. Lipton, C. Powell, P. Harris, A. M. Countouriotis, T. H. BrummendorfBrd. 2 Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia inchronic phase (CML-CP): Two-year follow-up from DASISION. (Abstract#6510)H. Kantarjian, N. P. Shah, J. E. Cortes, M. Baccarani, M. Bradley-Garelik, C. Zhu,A. HochhausBrd. 3 Comparison of nilotinib and imatinib in patients (pts) with newly diagnosedchronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-monthfollow-up. (Abstract #6511)R. A. Larson, D. Kim, G. Rosti, L. Stenke, R. Pasquini, A. Hoenekopp,R. E. Blakesley, N. J. Gallagher, A. Hochhaus, T. P. Hughes, G. Saglio,H. KantarjianBrd. 4 Five-year follow-up of patients with imatinib-resistant or -intolerant chronicphasechronic myeloid leukemia (CML-CP) receiving dasatinib. (Abstract#6512)N. P. Shah, J. E. Cortes, C. A. Schiffer, F. Guilhot, T. H. Brummendorf, A. C. Chen,D. Healey, A. Lambert, G. SaglioBrd. 5 A survey of current practices in the management of chronic myeloidleukemia (CML). (Abstract #6513)M. J. Mauro, J. E. Cortes, R. A. Larson, P. M. Herout, V. K. Bollu, A. Niyazov,H. KantarjianBrd. 6 Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment ofmyelofibrosis. (Abstract #6514)A. D. Pardanani, D. Caramazza, G. George, T. L. Lasho, W. J. Hogan,M. R. Litzow, K. Begna, C. A. Hanson, R. F. McClure, L. M. Bavisotto,G. Smith, M. Kowalski, S. Sirhan, A. W. Roberts, V. Gupta, J. Gotlib, A. Tefferi74